摘要
目的:分析影响前列腺增生患者经尿道前列腺等离子切除术(plasmakinetic resection of the prostate,PKRP)治疗疗效的影响因素。方法:回顾性分析2018年3月至2019年3月本院收治的96例前列腺增生患者临床资料,所有患者均进行PKRP治疗,分析治疗后影响PKRP治疗疗效的相关因素。结果:96例患者PKRP治疗都顺利完成,治疗有效率为86.46%(83/96),手术时间74~110 min,平均90.13 min;根据治疗疗效分组,两组患者糖尿病、高血压、冠心病等基础疾病比例、手术时间、QOL评分等比较差异无统计学意义(P>0.05);治疗有效组患者年龄、病程、术后尿导管留置时间、IPSS评分均小于、短于或低于治疗无效组(P<0.05),治疗有效组前列腺体积、长期饮酒人数大于或多于治疗无效组(P<0.05);年龄、术前尿路感染、IPSS、前列腺大小、长期饮酒是影响前列腺增生PKRP治疗疗效的独立危险因素。结论:年龄、术前尿路感染、IPSS、前列腺大小、饮酒是影响前列腺增生PKRP治疗疗效的独立危险因素,对于合并危险因素者,临床治疗过程中需引起重视。
Objective:To analyze the influencing factors on the therapeutic efficacy of plasmakinetic resection of the prostate(PKRP)in patients with benign prostatic hyperplasia.Methods:The clinical data of 96 patients with benign prostatic hyperplasia admitted to our hospital from March 2018 to March 2019 were retrospectively analyzed.All patients were treated with PKRP,and the related factors affecting the efficacy of PKRP after treatment were analyzed.Results:PKRP was successfully completed in 96 patients,and the effective rate was 86.46%;the operation time was 74-110 min,with an average of 90.13 min.According to the treatment efficacy,there was no significant difference in the proportion of basic diseases such as diabetes,hypertension and coronary heart disease,operation time and QOL score between the two groups(P>0.05).The age,course of disease,postoperative urinary catheter indwelling time and IPSS score in the effective treatment group were less,shorter or lower than those in the ineffective treatment group(P<0.05),the prostate volume and the number of long-term drinking in the effective treatment group were greater or more than those in the ineffective treatment group(P<0.05).The age,preoperative urinary tract infection,IPSS,prostate size,and long-term alcohol consumption were independent risk factors that affected the efficacy of PKRP treatment for patients with prostatic hyperplasia.Conclusion:Age,preoperative urinary tract infection,IPSS,prostate size,and alcohol consumption are independent risk factors that affect the efficacy of PKRP in the treatment of prostatic hyperplasia.For patients with combined risk factors,attention should be paid to the clinical treatment process.
作者
梁其炎
LIANG Qiyan(Department of Urology,Yangjiang People's Hospital,Yangjiang 529500,Guangdong,China)
出处
《包头医学院学报》
CAS
2022年第5期10-12,46,共4页
Journal of Baotou Medical College
基金
广东省阳江市医疗卫生类科技计划项目(社发[2018]24)。
关键词
前列腺增生
PKRP
多因素预测
Prostate Hyperplasia
PKRP Treatment
Influencing Factors
Prediction
Research